Adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research
Market Size
The global Live Cell Imaging market size is projected to reach USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9%.
Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), and NanoEnTek Inc. (Korea) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.
For More Details, Download a PDF Brochure:-
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483
“Danaher dominated the live cell imaging market in 2017”
The company is a global leader in live cell imaging and has been operating in the market for about 50 years. Its innovative capabilities are evident from the products the company has launched in recent years, such as the SP8 FALCON launched in March 2018, which is an integrated contrast microscope that enables researchers to monitor interactions between proteins in living cells. R&D is a key area of focus for Danaher—it invested USD 1.13 billion in R&D activities in 2017. The company focuses on improving its R&D capabilities to unlock additional synergies and growth opportunities.
“Carl Zeiss is another dominant player in the live cell imaging market”
The leading position of the company is attributed to its brand recognition and its innovative quality products. The company’s Center for Application and Research in Bangalore (India) and the Carl Zeiss Innovations Center for Research and Development in Shanghai (China) strengthened its presence in the rapidly developing economies of the APAC region. In March 2017, Carl Zeiss entered into a partnership with Carl R. Woese Institute for Genomic Biology (IGB) (US) to provide researchers around the US with access to the advanced technologies offered by Zeiss including the ZEISS Celldiscoverer 7, at IGB’s Core Facilities.
We can help with your specific research requirement for this market. Please share your specific interest to help us serve you better, Request Sample Pages:-
https://www.marketsandmarkets.com/requestsampleNew.asp?id=163914483
